Development of Antibodies with Broad Neutralization Specificities against HIV-1 after Long Term SHIV Infection in Macaques

被引:5
作者
Gao, Nan [1 ]
Gai, Yanxin [1 ]
Meng, Lina [1 ]
Wang, Chu [1 ]
Zhang, Xin [1 ]
Wang, Wei [2 ,3 ]
Qin, Chuan [2 ,3 ]
Yu, Xianghui [1 ,4 ]
Gao, Feng [1 ,5 ]
机构
[1] Jilin Univ, Sch Life Sci, Natl Engn Lab AIDS Vaccine, Changchun 130012, Peoples R China
[2] Chinese Acad Med Sci, Inst Lab Anim Sci, Beijing 100021, Peoples R China
[3] Peking Union Med Coll, Comparat Med Ctr, Beijing 100021, Peoples R China
[4] Jilin Univ, Sch Life Sci, Key Lab Mol Enzymol & Engn, Minist Educ, Changchun 130012, Peoples R China
[5] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
来源
VIRUSES-BASEL | 2020年 / 12卷 / 02期
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
simian; human immunodeficiency virus; neutralizing antibody; specificities; non-human primate; escape mutation; MONOCLONAL-ANTIBODIES; DEPENDENT EPITOPE; RHESUS MACAQUES; POTENT; RESPONSES; IDENTIFICATION; LINEAGES;
D O I
10.3390/v12020163
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Non-human primates (NHP) are the only animal model suitable to evaluate the protection efficacy of HIV-1 vaccines. It is important to understand how and when neutralizing antibodies (nAbs) with specificities similar to those of human broadly neutralizing antibodies (bnAbs) develop in NHPs. To address these questions, we determined plasma neutralization specificities in two macaques which developed neutralization breadth after long-term simian/human immunodeficiency virus (SHIV) infection and identified neutralization escape mutations by analyzing the env sequences from longitudinal plasma samples. Neutralization activities targeting V2, CD4bs, V3 and gp120-gp41 interface only became detectable in week 350 plasma from macaques G1015R and G1020R using 25710 env mutants. When mapped with CAP45 env mutants, only V2 specificity was detected at week 217 and persisted until week 350 in G1015R. Neutralization escape mutations were found in CD4bs and V2 regions. However, all of them were different from those resistant mutations identified for human bnAbs. These results show that nAbs with specificities similar to human bnAbs are only detectable after long-term SHIV infection and that neutralization escape mutations in macaques are different from those found in HIV-1-infected individuals. These findings can have important implications in the best utilization of the NHP model to evaluate HIV-1 vaccines.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Identification of an HIV-1 Clade A Envelope That Exhibits Broad Antigenicity and Neutralization Sensitivity and Elicits Antibodies Targeting Three Distinct Epitopes
    Hoffenberg, Simon
    Powell, Rebecca
    Carpov, Alexei
    Wagner, Denise
    Wilson, Aaron
    Pond, Sergei Kosakovsky
    Lindsay, Ross
    Arendt, Heather
    DeStefano, Joanne
    Phogat, Sanjay
    Poignard, Pascal
    Fling, Steven P.
    Simek, Melissa
    LaBranche, Celia
    Montefiori, David
    Wrin, Terri
    Pham Phung
    Burton, Dennis
    Koff, Wayne
    King, C. Richter
    Parks, Christopher L.
    Caulfield, Michael J.
    JOURNAL OF VIROLOGY, 2013, 87 (10) : 5372 - 5383
  • [32] A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques
    Zhang, Peng
    Narayanan, Elisabeth
    Liu, Qingbo
    Tsybovsky, Yaroslav
    Boswell, Kristin
    Ding, Shilei
    Hu, Zonghui
    Follmann, Dean
    Lin, Yin
    Miao, Huiyi
    Schmeisser, Hana
    Rogers, Denise
    Falcone, Samantha
    Elbashir, Sayda M.
    Presnyak, Vladimir
    Bahl, Kapil
    Prabhakaran, Madhu
    Chen, Xuejun
    Sarfo, Edward K.
    Ambrozak, David R.
    Gautam, Rajeev
    Martin, Malcom A.
    Swerczek, Joanna
    Herbert, Richard
    Weiss, Deborah
    Misamore, Johnathan
    Ciaramella, Giuseppe
    Himansu, Sunny
    Stewart-Jones, Guillaume
    McDermott, Adrian
    Koup, Richard A.
    Mascola, John R.
    Finzi, Andres
    Carfi, Andrea
    Fauci, Anthony S.
    Lusso, Paolo
    NATURE MEDICINE, 2021, 27 (12) : 2234 - +
  • [33] Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses
    Scheepers, Cathrine
    Chowdhury, Sudipa
    Wright, W. Shea
    Campbell, Christopher T.
    Garrett, Nigel J.
    Karim, Quarraisha Abdool
    Karim, Salim S. Abdool
    Moore, Penny L.
    Gildersleeve, Jeffrey C.
    Morris, Lynn
    AIDS, 2017, 31 (16) : 2199 - 2209
  • [34] Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth
    Murphy, Megan K.
    Yue, Ling
    Pan, Ruimin
    Boliar, Saikat
    Sethi, Anurag
    Tian, Jianhui
    Pfafferot, Katja
    Karita, Etienne
    Allen, Susan A.
    Cormier, Emmanuel
    Goepfert, Paul A.
    Borrow, Persephone
    Robinson, James E.
    Gnanakaran, S.
    Hunter, Eric
    Kong, Xiang-Peng
    Derdeyn, Cynthia A.
    PLOS PATHOGENS, 2013, 9 (02)
  • [35] Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein
    Klein, Florian
    Gaebler, Christian
    Mouquet, Hugo
    Sather, D. Noah
    Lehmann, Clara
    Scheid, Johannes F.
    Kraft, Zane
    Liu, Yan
    Pietzsch, John
    Hurley, Arlene
    Poignard, Pascal
    Feizi, Ten
    Morris, Lynn
    Walker, Bruce D.
    Faetkenheuer, Gerd
    Seaman, Michael S.
    Stamatatos, Leonidas
    Nussenzweig, Michel C.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2012, 209 (08) : 1469 - 1479
  • [36] Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development
    Malherbe, Delphine C.
    Wibmer, Constantinos Kurt
    Nonyane, Molati
    Reed, Jason
    Sather, D. Noah
    Spencer, David A.
    Schuman, Jason T.
    Guo, Biwei
    Pandey, Shilpi
    Robins, Harlan
    Park, Byung
    Fuller, Deborah H.
    Sacha, Jonah B.
    Moore, Penny L.
    Hessell, Ann J.
    Haigwood, Nancy L.
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [37] Protective immunity of gene-deleted SHIVs having an HIV-1 Env against challenge infection with a gene-intact SHIV
    Ui, M
    Kuwata, T
    Igarashi, T
    Miyazaki, Y
    Tamaru, K
    Shimada, T
    Nakamura, M
    Uesaka, H
    Yamamoto, H
    Hayami, M
    JOURNAL OF MEDICAL PRIMATOLOGY, 1999, 28 (4-5) : 242 - 248
  • [38] Anti-V3 Monoclonal Antibodies Display Broad Neutralizing Activities against Multiple HIV-1 Subtypes
    Hioe, Catarina E.
    Wrin, Terri
    Seaman, Michael S.
    Yu, Xuesong
    Wood, Blake
    Self, Steve
    Williams, Constance
    Gorny, Miroslaw K.
    Zolla-Pazner, Susan
    PLOS ONE, 2010, 5 (04):
  • [39] Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth
    Li, Yifan
    Bai, Hongjun
    Sanders-Buell, Eric
    Dussupt, Vincent
    Townsley, Samantha
    Donofrio, Gina
    Bose, Meera
    O'Sullivan, Anne Marie
    Kibuuka, Hannah
    Maganga, Lucas
    Nitayaphan, Sorachai
    Kosgei, Josphat
    Pitisuttithum, Punnee
    Rerks-Ngarm, Supachai
    Eller, Leigh Anne
    Michael, Nelson L.
    Robb, Merlin L.
    Ake, Julie
    Vasan, Sandhya
    Tovanabutra, Sodsai
    Krebs, Shelly J.
    Rolland, Morgane
    JOURNAL OF VIROLOGY, 2021, 95 (17)
  • [40] Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV Challenge
    Chege, Gerald K.
    Chapman, Rosamund E.
    Keyser, Alana T.
    Adams, Craig H.
    Benn, Kealan
    van Diepen, Michiel T.
    Douglass, Nicola
    Lambson, Bronwen
    Hermanus, Tandile
    Moore, Penny L.
    Williamson, Anna-Lise
    VIRUSES-BASEL, 2025, 17 (02):